Equilab International

What Equilab International does

Equilab International (PT Equilab International) is an Indonesia-based, privately held Contract Research Organization founded in 2003 and headquartered in Jakarta. It is the first CRO established in Indonesia and positions itself as the largest CRO in the country and a leading one in Southeast Asia, offering four integrated service lines: bioequivalence and pharmacokinetics studies, end-to-end clinical trials, central laboratory testing (pharmaceutical, cosmetic, food and beverage, and clinical chemistry), and dermatology testing (SPF, HRIPT, hypoallergenic, and other safety and efficacy studies). The company runs bioanalysis on advanced instrumentation including LC-MS/MS, HPLC (UV/FL/RID), GC (FID/MS), ICP-OES, ELISA, and spectrophotometers, supported by more than 250-300 validated bioanalytical methods, a 126-site clinical network across Indonesia, and accreditations that include UK MHRA, Malaysian NPRA, BPOM Maturitas Level 4, WHO Prequalification (first ASEAN CRO to receive it, 2021), ISO/IEC 17025, and ISO/IEC 15189.

The business operates on a B2B professional services model. Equilab sells contracted research services directly to enterprise clients in pharmaceuticals, biotechnology, cosmetics, and food and beverage, generating revenue on a per-project or per-study basis. Its client base spans 100+ international sponsors across 40+ countries and 300+ domestic partners, with study reports recognized by regulators including WHO and UK MHRA. The company has completed more than 1,500 projects, managed 32,000+ vaccine trial participants and 2,700+ infectious disease trial participants, and is managed by President Director Ronal Simanjuntak and Director Wimala Widjaja. Recent strategic activity has centered on (i) expanding from CRO-only into broader central laboratory and food testing services, (ii) deepening academic and specialty hospital partnerships to access oncology, neurology, and metabolic disease trials, and (iii) selectively engaging with regulators (BPOM, Ministry of Health) on the national clinical trial ecosystem via INA-CRC. Equilab has not raised disclosed external funding, has no parent company, and appears to be funded organically through operations.

Name

Equilab International

Legal name

PT Equilab International

Website

https://equilab-int.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

Equilab International is an Indonesia-headquartered Contract Research Organization founded in 2003 that provides bioequivalence studies, clinical trials, central laboratory testing, and dermatology testing to pharmaceutical, biotech, cosmetic, and food and beverage companies across 40+ countries.

Ownership category

akta.pro rank

Product category

Contract Research Organization Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Contract research organization
• Bioequivalence studies
• Clinical trial services
• Central laboratory testing
• Pharmaceutical testing

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Contract Research Services: Equilab generates revenue through providing contracted research services including bioequivalence studies, clinical trials, laboratory testing, and dermatology testing to pharmaceutical, biotech, food, and cosmetic companies. Services are billed per project or study conducted.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Equilab International is a Jakarta-based contract research organization (CRO) founded in 2003 that delivers bioequivalence and pharmacokinetic studies, clinical trial management, central laboratory testing, and dermatology testing services. The firm serves pharmaceutical, biotechnology, cosmetics, and food and beverage companies across Indonesia and the broader region.

Product overview

Equilab International is a Contract Research Organization (CRO) providing a comprehensive suite of research and testing services as a single unified offering rather than a modular platform architecture. The core portfolio consists of four main service lines: (1) Bioequivalence & Pharmacokinetics - providing BA/BE studies, bioavailability studies, complex dosage form studies, and biosimilar studies; (2) Clinical Trials - delivering end-to-end clinical trial services across multiple therapeutic areas; (3) Central Laboratory Testing - encompassing pharmaceutical testing, cosmetics testing, food and beverage testing, and clinical laboratory testing; and (4) Dermatology Testing - including efficacy studies (SPF, PA, claim validations) and safety studies (HRIPT, hypoallergenic). These services are interconnected, with central laboratory testing supporting bioequivalence and clinical trial work, while dermatology testing serves the cosmetics industry clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioequivalence and Pharmacokinetics Studies Full-service bioequivalence (BE) and pharmacokinetic (PK) studies covering a broad range of dosage forms (tablets, capsules, orally disintegrating tablets, soft gelatin capsules, granules/syrups, suspensions, and vaccines) for pharmaceutical companies seeking regulatory approval and market entry. The offering is delivered through a 96-bed clinical facility, GMP-compliant processes, and bioanalytical method development.
• Clinical Trial Management End-to-end clinical trial services including site management, clinical conduct, and bioanalytical support for vaccine and pharmaceutical trials. Recent projects include collaborative vaccine bioequivalence trials with US pharmaceutical partners.
• Central Laboratory Testing Centralized analytical laboratory testing covering heavy metal analysis, microbiological testing, chemical composition analysis, and physical testing. Equipped with LC-MS/MS, HPLC-UV/FL/RID, GC FID/MS, ICP-OES, ELISA, and spectrophotometers, the lab serves pharmaceutical, food, beverage, and cosmetics manufacturers.
• Dermatology Testing Dermatology-focused clinical and laboratory testing services, including irritation, sensitization, and safety assessments of cosmetic and pharmaceutical products on human subjects, used by cosmetics and personal care companies for product claims and regulatory submissions.

Quantifiable outcome

• 1,500+ successful projects completed
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• School of Pharmacy, Institut Teknologi Bandung (ITB)coreStrategic or Co-development Partner · 25 May 2026MoA signed on May 25, 2026 marking strategic collaboration for research, education, and clinical research capabilities in Indonesia. Joint project scheduled to commence June 2026. Collaboration includes educational programs such as internships, lectures, seminars, and symposiums in clinical research and laboratory testing.
• UGM Academic Hospital (Rumah Sakit Akademik Universitas Gadjah Mada)coreStrategic or Co-development Partner · 10 February 2026Clinical trial agreement signed February 10, 2026 to strengthen clinical trial projects in Indonesia. Agreement signed by Ronal Simanjuntak, President Director of Equilab International, and Dr. dr. Darwito, S.H., Sp.B(K)On, Director of RSA UGM.
• National Brain Center Hospital (RS PON Prof. Dr. dr. Mahar Mardjono)coreStrategic or Co-development Partner · 1 December 2025First strategic collaboration formalized with Clinical Research Unit (CRU) of RS PON. Initial collaboration focuses on GLP-1 receptor agonist (semaglutide) diabetes drug trial. Partnership synergizes clinical operations with advanced laboratory analysis.
• Asosiasi Pengusaha Suplemen Kesehatan Indonesia (APSKI)minorStrategic or Co-development Partner · 22 October 2025Official visit on October 22, 2025 to strengthen synergy in testing supplements, traditional medicines, and cosmetic products. Collaboration encompasses clinical trials, laboratory testing, and dermatology testing.
• BPOM (Badan Pengawas Obat dan Makanan) Republic of IndonesiacoreStrategic or Co-development Partner · 10 September 2025High-level delegation visit led by Deputy I dr. William Adi Teja to discuss BA/BE and clinical trial ecosystem. Strategic collaboration to enhance both volume and quality of clinical trials nationally.
• Material Transfer Agreement (MTA) Committee - Ministry of Health IndonesiaminorStrategic or Co-development Partner · 1 June 2025Visit by MTA Committee led by Prof. Dr. Muhammad Nasrum Massi to monitor clinical trial and sample analysis capabilities. Equilab obtained eight MTA approvals over past five years.
• RSUD Dr. SoetomocoreStrategic or Co-development Partner · 3 February 2025MoU signed February 3, 2025 for oncology clinical trials. Partnership combines academic clinical excellence with professional study management. Planned collaboration includes prostate cancer drug trial with more studies in upcoming months.
• Ministry of Health of the Republic of Indonesia (INA-CRC)coreStrategic or Co-development Partner · 16 October 2024Invitation to INA-CRC launch hosted by Ministry of Health. Deputy Minister inaugurated INA-CRC as national center to coordinate clinical trials in Indonesia. Commitment to accelerate clinical trial approval process.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• ICON plc: Global CRO and lab services provider with bioanalytical, central lab, and clinical operations across 90+ countries. Overlaps with Equilab in central lab, clinical, and bioanalytical services for pharma/biotech sponsors.
• Novotech (Novotech Health Holdings): Asia-Pacific-focused full-service CRO with multi-country site networks across the region. Comparable to Equilab as a regional Asia CRO serving international sponsors, but operates at significantly larger scale and broader geography.
• Parexel International: Global CRO providing clinical trials, bioanalytical, and regulatory services to pharma and biotech. Comparable in bioequivalence and clinical operations, but with global geographic reach Equilab does not have.
• IQVIA: Largest global CRO with end-to-end clinical, bioanalytical, and real-world evidence services. Comparable to Equilab in clinical trial execution and bioanalytical offerings, though at global scale and across many more geographies.
• Charles River Laboratories: Global CRO/CDMO with significant bioanalytical and preclinical capabilities, including work in emerging markets. Overlaps with Equilab on bioanalytical method development and BA/BE studies but serves a far broader sponsor base globally.

Emerging players

• BioAgilytix Labs: Specialized bioanalytical CRO with strong PK/PD, immunogenicity, and biomarker capabilities for biologics and biosimilars. Comparable to Equilab's bioanalytical method library (Semaglutide, Somatropin) and growing biologics focus.

Direct peers

• Veeda Clinical Research: India-based CRO specializing in bioequivalence and Phase I clinical trials with validated bioanalytical capabilities. Comparable to Equilab in BA/BE focus, regulatory-grade bioanalytical methods, and emerging-market generics/biologics sponsor base.
• Cliantha Research: India-headquartered full-service CRO offering bioequivalence, bioanalytical, clinical, and dermatology testing services across emerging markets. Directly comparable to Equilab in service mix (BA/BE + central lab + cosmetics) and in targeting global generics sponsors seeking non-Western CRO capacity.
• Accutest Research Laboratories: Indian CRO offering bioanalytical, BA/BE, and clinical trial services with strong bioanalytical method libraries. Directly comparable to Equilab's bioanalytical method depth (300+ methods) and emerging-market generics sponsor model.

Regional players

• PT Pharma Metric International: Indonesia-headquartered CRO offering bioequivalence and clinical research services. Direct local competitor to Equilab in the Indonesian market with overlapping BA/BE and clinical trial offerings.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/equilab-international
• Facebookfacebook.com/profile.php

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Equilab International